Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19507660rdf:typepubmed:Citationlld:pubmed
pubmed-article:19507660lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:19507660lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19507660lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:19507660lifeskim:mentionsumls-concept:C0025219lld:lifeskim
pubmed-article:19507660lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:19507660pubmed:issue5lld:pubmed
pubmed-article:19507660pubmed:dateCreated2009-6-10lld:pubmed
pubmed-article:19507660pubmed:abstractTextMelatonin has been suggested to have antiproliferative effects on cancer cells. These effects can be attributed to immunomodulation, growth factor inhibition, induction of apoptosis and prooxidant properties. Melatonin is considered as a safe drug with minimal adverse effects.lld:pubmed
pubmed-article:19507660pubmed:languageenglld:pubmed
pubmed-article:19507660pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19507660pubmed:citationSubsetIMlld:pubmed
pubmed-article:19507660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19507660pubmed:statusMEDLINElld:pubmed
pubmed-article:19507660pubmed:issn0006-9248lld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:ArslanMehmetMlld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:AydinFazilFlld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:KavgaciHalilHlld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:OzdemirFeyyaz...lld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:KaynarKubraKlld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:DenizOzlenOlld:pubmed
pubmed-article:19507660pubmed:authorpubmed-author:YildizBulentBlld:pubmed
pubmed-article:19507660pubmed:issnTypePrintlld:pubmed
pubmed-article:19507660pubmed:volume110lld:pubmed
pubmed-article:19507660pubmed:ownerNLMlld:pubmed
pubmed-article:19507660pubmed:authorsCompleteYlld:pubmed
pubmed-article:19507660pubmed:pagination276-9lld:pubmed
pubmed-article:19507660pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:meshHeadingpubmed-meshheading:19507660...lld:pubmed
pubmed-article:19507660pubmed:year2009lld:pubmed
pubmed-article:19507660pubmed:articleTitleThe effects of melatonin on human hepatoma (Hep G2) cell line.lld:pubmed
pubmed-article:19507660pubmed:affiliationDepartment of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey. feyyazozdemir@yahoo.comlld:pubmed
pubmed-article:19507660pubmed:publicationTypeJournal Articlelld:pubmed